Neutralising antibody responses to two doses of measles vaccine at 5 and 13 months of age in the United Kingdom.
Fifty-three children born in the United Kingdom between April 1993 and July 1994 were given two doses of measles vaccine, at 5 and 13 months of age, and their neutralising antibody reports were studied to assess the feasibility of protecting infants (aged 1 to 11 months) in the event of an outbreak or who were due to travel abroad. Sixteen infants responded at 5 months, an additional 35 responded at 13 months and two did not respond. The responses were inversely related to the levels of maternal antibodies (p < 0.0001). Infants who responded at 5 months also produced higher responses at 13 months than those who did not respond initially (p = 0.0001). No serious side effects were encountered. These data suggest that measles vaccine protects 30% of infants at 5 months and that a second dose at 13 months results in almost universal seroconversion.
Ko
B
B
Department of Community Paediatrics, Mid-Essex Health Authority, London. benko@northone.freeserve.co.uk
Roberts
D
D
Begg
N
N
Rao
M
M
Teare
L
L
Cohen
B
B
D000704:Analysis of Variance; D000914:Antibodies, Viral / Q000097:blood*; D006801:Humans; D007112:Immunity, Maternally-Acquired / Q000276:immunology; D007223:Infant; D008458:Measles Vaccine / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*; D009500:Neutralization Tests; D006113:United Kingdom
D000914:Antibodies, Viral; D008458:Measles Vaccine